Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Total Non-Current Liabilities (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Total Non-Current Liabilities data on record, last reported at $73.2 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $73.2 million; the TTM value through Sep 2025 reached $73.2 million, changed N/A, while the annual FY2024 figure was $218000.0, 99.07% down from the prior year.
  • Total Non-Current Liabilities reached $73.2 million in Q3 2025 per ZBIO's latest filing, up from $218000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $73.2 million in Q3 2025 and bottomed at $218000.0 in Q4 2024.
  • Average Total Non-Current Liabilities over 3 years is $32.3 million, with a median of $23.5 million recorded in 2023.
  • The widest YoY moves for Total Non-Current Liabilities: up 99.07% in 2024, down 99.07% in 2024.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $23.5 million in 2023, then tumbled by 99.07% to $218000.0 in 2024, then skyrocketed by 33463.76% to $73.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $73.2 million in Q3 2025, $218000.0 in Q4 2024, and $23.5 million in Q4 2023.